GO:0003106 negative regulation of glomerular filtration by angiotensin: Renal Hemodynamics, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003106 describes the biological process in which angiotensin directly lowers the glomerular filtration rate (GFR) in the kidney.
• Angiotensin II is the principal effector peptide of the renin-angiotensin system (RAS) that mediates this negative regulation of glomerular filtration.
• The process is central to renal hemodynamic control and sodium homeostasis, and its dysregulation contributes to hypertension, nephrotic syndrome, and cirrhosis-associated renal dysfunction.
• Key molecular players include AGT, REN, ACE, AGTR1, AGTR2, and downstream effectors such as podocyte proteins and Wnt/β-catenin signaling components.
• Experimental models for studying GO:0003106 include angiotensin receptor blockade (e.g., losartan), gene knockout, and CRISPR-engineered cell and animal models.
• Understanding this process is essential for developing therapies targeting RAS-mediated kidney injury and for interpreting GFR changes in cardiovascular and renal disease.
Description
The renin-angiotensin system (RAS) is a master regulator of blood pressure, fluid balance, and renal function. Within the kidney, angiotensin II exerts a direct negative effect on the glomerular filtration rate (GFR), a process formally annotated as GO:0003106, negative regulation of glomerular filtration by angiotensin. This biological process is distinct from systemic blood pressure effects because it specifically describes angiotensin's direct action on the glomerulus to decrease filtration. Researchers study GO:0003106 because it sits at the intersection of renal hemodynamics, sodium handling, and hormonal control. For example, losartan, an angiotensin receptor blocker, alters renal hemodynamics and function in fetal sheep, demonstrating the physiological relevance of angiotensin-mediated GFR regulation. In essential hypertension, abnormal sodium transport and atrial natriuretic peptide interact with RAS to modulate glomerular filtration. Moreover, conditions such as nephrotic syndrome and cirrhosis involve profound changes in renal sodium and water excretion that are tightly linked to angiotensin action. This article provides a research-grade overview of GO:0003106, covering its definition, molecular mechanisms, key genes, disease associations, and state-of-the-art methods including CRISPR-based models. All statements are grounded in peer-reviewed literature to support both human readers and AI-driven retrieval systems.
negative regulation of glomerular filtration by angiotensin At A Glance
| GO ID | GO:0003106 |
|---|---|
| GO term | negative regulation of glomerular filtration by angiotensin |
| Ontology | biological_process |
| Synonym | angiotensin-mediated regulation of glomerular filtration; regulation of glomerular filtration by angiotensin |
| Definition | The process in which angiotensin directly decreases the rate of glomerular filtration in the kidney. |
| Major function | Direct hormonal suppression of glomerular filtration rate by angiotensin peptides. |
| Related system | Renin-angiotensin system (RAS) |
| Key effector | Angiotensin II (Ang II) |
| Physiological context | Renal hemodynamics, sodium and water homeostasis, blood pressure regulation. |
What Is GO:0003106?
GO:0003106, negative regulation of glomerular filtration by angiotensin, is defined as the process in which angiotensin directly decreases the rate of glomerular filtration in the kidney. Glomerular filtration is the process whereby blood is filtered by the glomerulus into the renal tubule. This term captures a specific hormonal control mechanism: angiotensin, primarily angiotensin II, acts on the glomerular vasculature and possibly on podocytes to reduce the filtration rate, independent of systemic blood pressure changes.
Why Is negative regulation of glomerular filtration by angiotensin Important in Cell Biology?
GO:0003106 is critically important because it represents a direct hormonal mechanism by which the kidney modulates filtration in response to angiotensin. This process is fundamental to understanding how the body maintains sodium balance and blood pressure, and its dysregulation is implicated in hypertension, heart failure, nephrotic syndrome, and cirrhosis-associated renal dysfunction. Therapeutic blockade of the RAS, such as with losartan, directly interferes with this process, making it a prime target for cardiovascular and renal drug development.
• Provides a mechanistic explanation for how angiotensin II acutely reduces GFR, independent of systemic blood pressure.
• Central to sodium homeostasis and extracellular fluid volume regulation in health and disease.
• Dysregulated in essential hypertension, contributing to abnormal renal hemodynamics.
• Involved in nephrotic syndrome and cirrhosis, where renal sodium and water excretion are severely altered.
• Target of RAS-blocking drugs (e.g., losartan, ACE inhibitors) used to treat hypertension and kidney disease.
• Relevant to contrast media-induced nephropathy, where hemodynamic changes affect renal function.
• Linked to podocyte dysfunction and proteinuric kidney disease via Wnt/β-catenin signaling.
• Magnesium and blood pressure regulation intersect with renal mechanisms that include angiotensin effects.
• Key for interpreting GFR changes in clinical settings and for designing renoprotective therapies.
• Provides a foundation for CRISPR-based studies to dissect gene function in renal hemodynamics.
What Happens During negative regulation of glomerular filtration by angiotensin?
Angiotensin II Generation and Receptor Activation
In simple terms: The body produces angiotensin II, which then binds to specific receptors on kidney cells to start the process.
Angiotensin II is generated through the sequential cleavage of angiotensinogen by renin and angiotensin-converting enzyme (ACE). Once formed, angiotensin II binds to angiotensin II type 1 (AGTR1) and type 2 (AGTR2) receptors on glomerular cells, including mesangial cells, podocytes, and vascular smooth muscle cells. This receptor activation is the initiating step for the negative regulation of glomerular filtration. In essential hypertension, abnormal sodium transport and atrial natriuretic peptide can modulate this system, influencing the overall effect on GFR.
Glomerular Hemodynamic Changes
In simple terms: Angiotensin II makes the kidney's filtering units tighten up, reducing blood flow and filtration.
Activation of AGTR1 by angiotensin II causes vasoconstriction of the afferent and efferent arterioles, with a preferential effect on the efferent arteriole. This increases intraglomerular pressure initially but ultimately reduces renal plasma flow and the ultrafiltration coefficient, leading to a decrease in GFR. Studies using losartan in fetal sheep demonstrate that blocking AGTR1 alters renal hemodynamics and function, confirming the direct role of angiotensin in this process. Contrast media can also induce hemodynamic changes in the kidney, highlighting the sensitivity of glomerular filtration to vasoactive substances.
Tubular and Sodium Handling Interactions
In simple terms: The kidney's handling of salt and water is tightly linked to how much it filters, and angiotensin coordinates both.
Angiotensin II also directly stimulates sodium reabsorption in the proximal tubule, which is coupled with the reduction in GFR to maintain sodium balance. In essential hypertension, abnormal Na+ transport and atrial natriuretic peptide interact with the RAS to modulate glomerular filtration. In nephrotic syndrome and cirrhosis, renal sodium and water excretion are profoundly altered, and angiotensin-mediated changes in GFR contribute to these disturbances. Thus, GO:0003106 is not an isolated event but part of an integrated renal response.
Podocyte and Glomerular Barrier Effects
In simple terms: Angiotensin can also affect the specialized cells that form the kidney's filtration barrier, potentially contributing to protein leakage.
Beyond hemodynamics, angiotensin II can directly affect podocytes, the specialized cells that form the glomerular filtration barrier. Activation of Wnt/β-catenin signaling in podocytes has been linked to podocyte dysfunction and proteinuric kidney disease, and RAS activation may intersect with this pathway. This suggests that the negative regulation of glomerular filtration by angiotensin may involve both hemodynamic and structural components, although the exact molecular links require further study.
Key Genes Involved in GO:0003106 negative regulation of glomerular filtration by angiotensin
The following genes and proteins are central to the renin-angiotensin system and the regulation of glomerular filtration by angiotensin, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGT | Precursor of angiotensin peptides | Target for studying angiotensin generation and GFR regulation |
| REN | Enzyme that cleaves angiotensinogen to angiotensin I | Rate-limiting step in RAS; knockout models alter GFR |
| ACE | Converts angiotensin I to angiotensin II | Key therapeutic target (ACE inhibitors); affects glomerular filtration |
| AGTR1 | Angiotensin II type 1 receptor | Mediates vasoconstriction and GFR reduction; blocked by losartan |
| AGTR2 | Angiotensin II type 2 receptor | Counter-regulatory effects; modulates renal hemodynamics |
| ACE2 | Converts angiotensin II to angiotensin-(1-7) | Protective axis; impacts renal function |
| MAS1 | Receptor for angiotensin-(1-7) | Opposes AGTR1 effects; relevant to GFR regulation |
| WNTS | Wnt ligands | Activate β-catenin in podocytes; linked to proteinuria |
| CTNNB1 | β-catenin | Podocyte dysfunction and proteinuric kidney disease |
| NPHS1 | Nephrin | Podocyte slit diaphragm protein; target of angiotensin effects |
| NPHS2 | Podocin | Podocyte foot process integrity; affected in proteinuria |
| SLC12A3 | Thiazide-sensitive NaCl cotransporter | Distal tubule sodium handling; interacts with RAS |
| SCNN1A | Epithelial sodium channel subunit | Aldosterone-sensitive sodium reabsorption; modulated in cirrhosis |
| NPPA | Atrial natriuretic peptide | Modulates GFR and sodium excretion; interacts with RAS |
| RENBP | Renin-binding protein | May regulate renin activity; potential role in RAS |
| AGTRAP | Angiotensin II receptor-associated protein | Modulates AGTR1 trafficking and signaling |
| CYP11B2 | Aldosterone synthase | Aldosterone production; affects sodium and GFR |
How Is negative regulation of glomerular filtration by angiotensin Regulated?
The process of negative regulation of glomerular filtration by angiotensin is itself regulated at multiple levels. Renin release from juxtaglomerular cells is controlled by renal perfusion pressure, distal tubular sodium delivery, and sympathetic nerve activity, all of which influence angiotensin II production. In essential hypertension, abnormal Na+ transport and atrial natriuretic peptide can modulate the sensitivity of the glomerulus to angiotensin. Additionally, in cirrhosis, remodeling of aldosterone target gene expression in the distal colon correlates with decaying kidney function, suggesting systemic regulation of RAS components. Magnesium and blood pressure regulation also intersect with renal mechanisms that include angiotensin effects. These regulatory layers ensure that GFR is finely tuned to the body's hemodynamic and volume status.
negative regulation of glomerular filtration by angiotensin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGTR1 | Hypertension, renal hemodynamic dysregulation | AGTR1 knockout or point-mutation cell lines; losartan treatment |
| REN | Essential hypertension, altered sodium regulation | REN knockout mice or CRISPR-edited renal cells |
| ACE | Hypertension, nephrotic syndrome | ACE knockout or overexpression models |
| CTNNB1 | Proteinuric kidney disease, podocyte dysfunction | Podocyte-specific β-catenin knockout or knock-in |
| SCNN1A | Cirrhosis-associated renal dysfunction | Colon or kidney-specific knockout; aldosterone target gene remodeling |
Hypertension and Renal Hemodynamics
In essential hypertension, the regulation of glomerular filtration by angiotensin is often dysregulated. Abnormal Na+ transport and atrial natriuretic peptide interact with the RAS to alter GFR, contributing to hypertension-related kidney damage. Losartan, an AGTR1 blocker, has been shown to affect cardiovascular and renal hemodynamics, underscoring the therapeutic relevance of this pathway.
Nephrotic Syndrome and Cirrhosis
Nephrotic syndrome and cirrhosis are characterized by profound disturbances in renal sodium and water excretion, in which angiotensin-mediated GFR regulation plays a key role. In cirrhosis, decaying kidney function correlates with remodeling of aldosterone target gene expression, indicating a link between RAS activation and renal dysfunction. These conditions highlight the clinical importance of understanding GO:0003106.
Proteinuric Kidney Disease and Podocyte Dysfunction
Wnt/β-catenin signaling in podocytes has been implicated in proteinuric kidney disease, and angiotensin II may influence this pathway. Podocyte dysfunction leads to proteinuria and altered glomerular filtration, connecting GO:0003106 to structural kidney injury. Targeting angiotensin signaling could therefore have protective effects beyond hemodynamic control.
Contrast Media-Induced Nephropathy
Contrast media can induce hemodynamic and tubular changes in the kidney, affecting GFR. Since angiotensin is a key regulator of renal hemodynamics, contrast-induced nephropathy may involve perturbations in GO:0003106. Understanding this interaction is important for preventing acute kidney injury in at-risk patients.
From negative regulation of glomerular filtration by angiotensin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AGTR1 mediate angiotensin-induced GFR reduction? | AGTR1 knockout cell line or mouse model |
| What is the role of ACE in angiotensin II generation and GFR? | ACE point-mutation or knockout models |
| How does β-catenin signaling in podocytes affect filtration? | Podocyte-specific CTNNB1 knock-in or knockout |
| Can overexpression of ACE2 protect against GFR decline? | ACE2 overexpression cell or animal model |
| What is the effect of REN mutations on renal hemodynamics? | REN knock-in of human mutations |
| How does SCNN1A contribute to cirrhosis-associated renal changes? | SCNN1A knockout in distal colon or kidney |
How to Study the negative regulation of glomerular filtration by angiotensin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Inulin clearance | Glomerular filtration rate | In vivo assessment of angiotensin effects |
| Losartan treatment | AGTR1 blockade effects on renal hemodynamics | Fetal sheep or rodent models |
| Wnt/β-catenin reporter assay | Podocyte signaling activation | Proteinuric kidney disease research |
| RNA sequencing | Transcriptomic changes in RAS activation | Cirrhosis and hypertension studies |
| CRISPR knockout screen | Genes affecting angiotensin signaling | Target discovery for GFR regulation |
| Proteomics | Protein expression and modifications | RAS pathway analysis |
| Calcium flux assay | AGTR1 activation | Drug screening and receptor studies |
| Immunohistochemistry | Protein localization in kidney | Podocyte and vascular studies |
In Vivo GFR Measurement
Glomerular filtration rate can be measured in animal models using inulin clearance, creatinine clearance, or imaging techniques. Studies in fetal sheep using losartan have demonstrated changes in renal hemodynamics and function, providing a model for assessing angiotensin effects on GFR. These methods are essential for validating the physiological relevance of GO:0003106.
Cellular and Molecular Assays
In vitro assays using podocytes, mesangial cells, and tubular epithelial cells can assess angiotensin signaling. For example, Wnt/β-catenin reporter assays in podocytes can measure pathway activation. Receptor binding assays and calcium flux measurements can quantify AGTR1 activation. These techniques help dissect the molecular mechanisms underlying GO:0003106.
Transcriptomics and Proteomics
RNA sequencing and proteomics can identify gene expression changes in response to angiotensin II or RAS blockade. In cirrhosis, remodeling of aldosterone target gene expression in the distal colon was linked to kidney function, illustrating the value of transcriptomic approaches. Such studies can reveal novel regulators of GO:0003106.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout screens can identify genes that modulate angiotensin signaling and GFR regulation. Bioinformatics analysis of RAS pathway components can predict interactions and guide experimental design. These approaches are powerful for discovering new therapeutic targets within GO:0003106.
How CRISPR Can Be Used to Study GO:0003106 negative regulation of glomerular filtration by angiotensin
Knockout
CRISPR knockout of AGTR1, ACE, or REN in cell lines or animal models can abolish angiotensin-mediated GFR regulation, providing causal evidence for their roles in GO:0003106. Knockout podocytes for CTNNB1 can test the link between Wnt signaling and filtration.
Point Mutation
Introducing point mutations in AGTR1 or REN that mimic human variants can reveal how specific amino acid changes affect receptor function and GFR regulation. Such models are valuable for studying hypertension-associated mutations.
Knock-in
Knock-in of human angiotensinogen or renin variants into mouse models can humanize the RAS and allow study of species-specific effects on glomerular filtration. This approach helps translate findings to human disease.
Overexpression
Overexpression of ACE2 or angiotensin-(1-7) components can counteract angiotensin II effects and protect against GFR decline. CRISPR-mediated overexpression in podocytes or tubular cells can model therapeutic interventions.
How EDITGENE Supports negative regulation of glomerular filtration by angiotensin Research
Researchers studying negative regulation of glomerular filtration by angiotensin-related genes often need to determine whether a candidate gene is causally involved in renal hemodynamics or merely a bystander. CRISPR-based models provide the precision required to establish causality, and EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of glomerular filtration by angiotensin research.
Frequently Asked Questions About negative regulation of glomerular filtration by angiotensin
What is GO:0003106?
GO:0003106 is the Gene Ontology term for negative regulation of glomerular filtration by angiotensin, describing how angiotensin directly decreases the glomerular filtration rate in the kidney.
What genes are involved in negative regulation of glomerular filtration by angiotensin?
Key genes include AGT, REN, ACE, AGTR1, AGTR2, ACE2, and MAS1, as well as podocyte genes like CTNNB1 and NPHS1.
How does angiotensin decrease glomerular filtration rate?
Angiotensin II binds to AGTR1 on glomerular cells, causing vasoconstriction and reducing the ultrafiltration coefficient, thereby lowering GFR.
What diseases are associated with GO:0003106?
Hypertension, nephrotic syndrome, cirrhosis, and proteinuric kidney disease are associated with dysregulation of this process.
What is the role of losartan in glomerular filtration?
Losartan blocks AGTR1, thereby inhibiting angiotensin-mediated GFR reduction and altering renal hemodynamics.
How can CRISPR be used to study GO:0003106?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of RAS genes in glomerular filtration.
What experimental models are used to study angiotensin effects on GFR?
Models include fetal sheep, rodent models, and cell culture systems such as podocytes and mesangial cells.
What is the connection between Wnt/β-catenin signaling and GO:0003106?
Wnt/β-catenin signaling in podocytes contributes to proteinuric kidney disease and may interact with angiotensin signaling to affect filtration.
How does cirrhosis affect angiotensin-mediated GFR regulation?
In cirrhosis, decaying kidney function correlates with remodeling of aldosterone target gene expression, indicating RAS involvement in renal dysfunction.
What methods are used to measure glomerular filtration rate in research?
Inulin clearance, creatinine clearance, and imaging techniques are commonly used to measure GFR in animal models.
Conclusion
GO:0003106, negative regulation of glomerular filtration by angiotensin, is a fundamental biological process that links the renin-angiotensin system to renal hemodynamics. Its dysregulation contributes to hypertension, nephrotic syndrome, cirrhosis, and proteinuric kidney disease, making it a critical area of research. Understanding the molecular players and regulatory mechanisms provides a foundation for developing targeted therapies. CRISPR-based models, combined with advanced screening and bioinformatics, offer powerful tools to dissect this process and identify new therapeutic targets. EDITGENE's comprehensive services support researchers in creating precise genetic models to study GO:0003106 and related pathways.
References
- 1. Stevenson KM et al.. 1996. Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep.. Clin Exp Pharmacol Physiol 23(2):125-33 PMID: 8819640
- 2. Caiazza A et al.. 2014. Hemodynamic and tubular changes induced by contrast media.. Biomed Res Int 2014:578974 PMID: 24678510
- 3. Semplicini A et al.. 2002. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.. J Nephrol 15(5):489-96 PMID: 12455714
- 4. Jespersen B. 1997. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.. Dan Med Bull 44(2):191-207 PMID: 9151012
- 5. Zhou L et al.. 2015. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease.. Nat Rev Nephrol 11(9):535-45 PMID: 26055352
- 6. Kawabe H et al.. 1991. Importance of the renin-angiotensin system in sodium regulation in essential hypertension.. Am J Hypertens 4(2 Pt 1):119-25 PMID: 1826997
- 7. Kuriyama S. 2026. Magnesium and blood pressure regulation: systemic and renal mechanisms.. Hypertens Res PMID: 42552400
- 8. Serrano-Morillas N et al.. 2023. Decaying kidney function during cirrhosis correlates with remodeling of distal colon aldosterone target gene expression.. Am J Physiol Gastrointest Liver Physiol 325(4):G306-G317 PMID: 37461846
